TriSalus Life Sciences, Inc.
TLSI
$4.73
$0.368.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.88M | 45.15M | 40.21M | 35.99M | 32.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.88M | 45.15M | 40.21M | 35.99M | 32.14M |
| Cost of Revenue | 6.70M | 6.97M | 6.42M | 5.52M | 4.63M |
| Gross Profit | 38.18M | 38.19M | 33.79M | 30.47M | 27.51M |
| SG&A Expenses | 51.33M | 50.44M | 49.96M | 47.33M | 44.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.91M | 72.10M | 71.46M | 66.97M | 63.96M |
| Operating Income | -28.03M | -26.95M | -31.26M | -30.98M | -31.82M |
| Income Before Tax | -27.31M | -39.22M | -39.58M | -31.17M | -27.21M |
| Income Tax Expenses | 6.00K | 7.00K | 6.00K | -2.00K | 8.00K |
| Earnings from Continuing Operations | -27.31 | -39.23 | -39.58 | -31.17 | -27.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.31M | -39.23M | -39.58M | -31.17M | -27.21M |
| EBIT | -28.03M | -26.95M | -31.26M | -30.98M | -31.82M |
| EBITDA | -27.44M | -26.32M | -30.56M | -30.27M | -31.08M |
| EPS Basic | -1.37 | -1.79 | -1.97 | -1.13 | -1.12 |
| Normalized Basic EPS | -0.50 | -0.63 | -0.78 | -0.70 | -1.00 |
| EPS Diluted | -1.37 | -1.79 | -1.97 | -1.14 | -1.12 |
| Normalized Diluted EPS | -0.50 | -0.63 | -0.78 | -0.70 | -1.00 |
| Average Basic Shares Outstanding | 175.21M | 151.42M | 132.13M | 115.57M | 106.48M |
| Average Diluted Shares Outstanding | 175.21M | 151.42M | 132.13M | 115.57M | 106.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |